- S.Africa tells UN court Israel 'genocide' hit 'new and horrific stage'
- Man City's Ederson out of Premier League climax and FA Cup final
- 'Rappers and yodellers': Nagelsmann strikes balance in Euro 2024 squad
- England set to ban gender identity teaching in schools
- Serbia leases army HQ bombed by NATO to Trump son-in-law
- France deploys additional forces to quell New Caledonia unrest
- McIlroy faces emotional early test as PGA Championship begins
- Chelsea players 'love' Pochettino and must fight for him, says Palmer
- Germany boss Nagelsmann ignores Hummels to stick with regulars for Euros
- Sevilla great Navas to leave club in summer
- France accuses Azerbaijan of interference in New Caledonia riots
- European stocks dip from records, shrugging off gains elsewhere
- Toulouse's Chocobares eligible for Champions Cup final in spite of suspension
- Dutch EU opt-out on asylum could take 'years': Wilders to AFP
- Murray makes victorious comeback in Bordeaux
- China's Baidu posts weakest quarterly revenue growth in over a year
- EU probes Facebook, Instagram over child protection
- Inter's title party continues as off-field problems lurk
- A pariah in the West, Putin finds fans in Beijing
- Ukraine says halted Russian 'advance' in some Kharkiv zones
- Asian football body scraps term limits for top leaders
- Five Israeli troops killed by friendly fire in Gaza
- US military says aid pier anchored to Gaza beach
- Taiwan presidential banquet to showcase island's identity
- Easyjet CEO flies out in 2025 after seven years
- New Dutch coalition govt wants 'strictest' asylum policy
- Siemens to sell electrical motors business to KPS
- Lai Ching-te: from coal miner's son to Taiwan president
- Slovak PM in 'very serious' condition after assassination attempt
- France deploys troops, bans TikTok, to quell New Caledonia unrest
- Record Super Rugby try scorer Perenara backed for All Blacks return
- Indian record-breaker Chhetri to retire from international football
- Esperance, Ahly resume great African club rivalry in final
- Clutch day for Trump lawyers seeking to discredit Cohen at trial
- Turkey's 'mad honey' aphrodisiac that can knock you flat
- Xi, Putin hail ties as 'stabilising' force in chaotic world
- Consumer groups accuse Temu of manipulating online shoppers
- Premier League in the US? FIFA weighs allowing overseas games
- Xi hails Russia ties as 'conducive to peace' in Putin talks
- Celtics overpower Cavs, Mavs edge closer after beating Thunder
- Monet painting fetches $35 million at New York auction
- Putin meets Xi in Beijing seeking greater support for war effort
- Asian markets track Wall St records after US inflation data
- Pro-Turkey Syria mercenaries head to Niger to earn cash
- FIFA meets to award 2027 Women's World Cup under Gaza cloud
- Iraqi car bomb survivor eyes gold in Paris Paralympics
- The Greatest, the Baddest and the best: six undisputed heavyweight champions
- France deploys troops, bans TikTok to quell deadly New Caledonia unrest
- Coppola's epic 'Megalopolis' finally arrives at Cannes
- French prison van attack takes drug battle to 'worrying' new level
Biontech-Chef Sahin hält Krebs langfristig für kontrollierbar
Biontech-Chef Ugur Sahin sieht die Medizin auf guten Weg, "Krebs langfristig zu kontrollieren oder idealerweise zu heilen". "Ich sehe prinzipiell keinen Grund, warum nicht viele Krebsarten früher erkennbar und besser heilbar sein sollten", sagte Sahin dem Nachrichtenmagazin "Spiegel" nach einer Meldung vom Sonntag.
Hintergrund sei eine Entwicklung, die Sahin "die große Wissensrevolution" nennt - eine sich immer schneller drehende Spirale aus Fortschritt und Entwicklungssprüngen, getrieben von digitalen Technologien und künstlicher Intelligenz. "Alles geht heute sehr, sehr viel schneller als früher", sagte der Forscher und Firmenchef. "Erkenntnisse zu gewinnen, sie zu bestätigen, sie anzuwenden."
Sahin forscht seit Jahrzehnten an Krebs und ist Professor für experimentelle Onkologie an der Universitätsmedizin Mainz. Das von ihm gegründete Unternehmen Biontech forscht derzeit an knapp 30 neuen Krebstherapien und stützt sich dabei insbesondere auf künstliche Intelligenz. Ab 2026 hofft Sahin, dass dann erste Medikamente bereit für eine Zulassung sind. "Bis 2030 wollen wir ein großes Portfolio an Krebstherapien auf dem Markt haben", sagte der Biontech-Chef anlässlich des Weltkrebstages.
B.Shevchenko--BTB